A Phase 3 Randomized Open-label Study Comparing Bempegaldesleukin (NKTR-214) Plus Abstract TPS4595 Nivolumab to Sunitinib or Cabozantinib (Investigator's Choice) in Patients With Previously **Untreated Advanced Renal Cell Carcinoma**

Nizar M. Tannir¹, Neeraj Agarwal², Sumanta K. Pal³, Maria Nirvana Formiga⁴, Jun Guo⁵, Daniel J. George⁶, Konstantin Penkov⁷, Mary Ann Tagliaferri⁸, Alison L. Hannah⁸, Jenny Yanzhen Zhang⁸, Yining Du⁸, Bridget A. O'Keeffe⁸, Daniel C. Cho⁹

¹University of Texas MD Anderson Cancer Center, Houston, TX; ²University of Utah Huntsman Cancer Center, Duarte, CA; ⁴AC Camargo Cancer Center São Paulo, Brazil; ⁵Peking University Cancer Hospital and Institute, Beijing Shi, China; ⁶Duke University Cancer Institute, Durham, NC; ⁷Euromedservice, St. Petersburg, Russia; ⁸Nektar Therapeutics, San Francisco, CA; ⁹Perlmutter Cancer Center New York University Langone Health, New York, NY

BACKGROUND

- High-dose interleukin-2 (IL-2; aldesleukin) has been an important therapy for advanced renal cell carcinoma (RCC) where it elicits immune-mediated durable responses, including complete responses and potential cure in up to 9% of treated patients¹⁻³; however, its use is highly limited by its toxicity
- Bempegaldesleukin is a first-in-class IL-2 receptor pathway agonist that leverages the IL-2 pathway to stimulate peripheral and tumor immune responses (Figure 1)^{4,5}
 - Inactive prodrug (IL-2 releasably conjugated to an average of 6 polyethylene glycol [PEG] polymers; 6_{avg}-PEG-IL-2)
 - The active cytokines (2-PEG-IL-2 and 1-PEG-IL-2) directly activate and expand effector T cells and natural killer (NK) cells by preferentially binding to the CD122 (IL-2R $\beta\gamma$) subunit of the IL-2 receptor

PIVOT-09: STUDY DESIGN

• Approximately 600 patients will be randomized 1:1 into two treatment arms (Figure 3)

N=600

Figure 3: Study Schema

Population

Previously untreated advanced RCC

- Intermediate or poor IMDC prognostic score
- Tumor tissue available for PD-L1 testing

ASSESSMENTS AND FOLLOW-UP

Clinical

- Clinic visits: 6-week cycles with 3-week visit schedule
 - Study drug administration
 - Safety assessments
 - Quality of life assessments
 - PK and biomarker assessments (primarily Arm A)
- Tumor assessments:
 - Screening: CT/MRI chest, abdomen, pelvis (CAP) and brain
 - Post randomization: CT/MRI CAP and brain if history or clinical symptoms of
- Arm A^a Bempegaldesleukin 0.006 mg/kg IV q3w + Nivolumab 360 mg IV q3w

<u>Arm B</u>

Investigator's choice

Sunitinib 50 mg po qd

for 4 weeks, followed by

2 weeks off


OR

Cabozantinib 60 mg po qd

^aMaximum treatment duration 2 years

- Gradual release of PEG chains *in vivo* leads to sustained exposure to these active IL-2 cytokines

Figure 1: Bempegaldesleukin Preferential Signaling **Through IL-2Rβγ**



Approximately 150 sites (US, Latin America, Russia, Asia Pacific)

Stratification Factors

- PD-L1 status ($\geq 1\%$ vs < 1% or indeterminate)
- Intermediate vs poor IMDC prognostic score
- TKI choice (sunitinib vs cabozantinib)

Co-Primary Endpoints ORR by BICR per RECIST v1.1 • OS

Secondary Endpoints
• PFS by BICR per RECIST
• AEs

ST v1.1

QoL

PD-L1 biomarker

BICR, blinded independent central review; IMDC, International Metastatic Renal Cell Carcinoma Database Consortium; ORR, objective response rate; OS, overall survival; PD-L1, programmed cell death ligand 1; PFS, progression-free survival; QoL, quality of life; RCC, renal cell carcinoma; RECIST v1.1, Response Evaluation Criteria in Solid Tumors version 1.1; q3w, every 3 weeks; qd, daily; TKI, tyrosine kinase inhibitor.

ELIGIBILITY

Key Inclusion Criteria

brain metastases

- Frequency: every 9 weeks through week 54, then every 12 weeks until **RECIST** progression
- Safety follow up visit 30 days after last dose of study treatment
- Additional safety follow up 100 days after last dose of nivolumab (if applicable)
- Survival follow up approximately every 12 weeks
 - Includes collection of subsequent anticancer therapy and PFS2 data

Biomarkers and Pharmacokinetics

- Assessment of biomarkers potentially predictive of clinical responses to bempegaldesleukin combined with nivolumab or to TKI
- PK profiling of bempegaldesleukin and its metabolites (plasma) and nivolumab (serum)

STATISTICAL PLAN


- Study sample size accounts for the 2 co-primary efficacy endpoints: ORR and OS
- ORR analysis will occur when the first ~400 patients have a minimum follow-up of 6 months
- Overall Survival (OS) analysis will follow the promising zone adaptive design¹³
 - At the interim analysis for OS, an independent Data Monitoring Committee will set the number of OS events required in order to provide 90% conditional power for the final analysis
 - The target Hazard Ratio for OS is 0.65 (assuming median OS of 26.5 months for the control arm)

STUDY RATIONALE

• First-line therapy for advanced RCC is rapidly evolving, and preferred regimens⁶ currently include:

- Monotherapy with tyrosine kinase inhibitors (TKI) of angiogenesis (sunitinib or cabozantinib)^{7,8}
- Combination of immune checkpoint inhibitors (ICIs) (nivolumab + ipilimumab)⁹
- Combination of TKI and ICI (axitinib + pembrolizumab or avelumab)^{10,11}
- In a phase 2 clinical study, bempegaldesleukin + nivolumab demonstrated encouraging efficacy in frontline advanced RCC independent of PD-L1 status (Figure 2)¹²
 - Objective response rate (ORR) of 46% (12/26 patients with complete or partial response)
 - 53% (9/17) ORR in RCC patients with tumors lacking PD-L1 expression
- The combination of bempegaldesleukin + nivolumab was generally well tolerated among patients with different tumor types (N=283)¹²
 - Most common treatment-related adverse events (TRAEs) were low-grade cytokine-related events (flu-like symptoms [59%], rash [45%], fatigue [42%], pruritis [31%])
 - Grade \geq 3 TRAEs 14%
 - Low rate of discontinuation due to TRAEs (2%)
- Bempegaldesleukin + nivolumab offers a potential novel combination immunooncology treatment option for patients with advanced RCC

Figure 2: Clinical Data in First-Line RCC Patients



Advanced RCC with clear cell component including tumors with sarcomatoid features

• Archival tissue (≤12 months) or fresh biopsy for PD-L1 test before randomization

• Measurable disease per RECIST v1.1 criteria (by local investigator)

• IMDC intermediate/poor risk (based on central laboratory results)

• Karnofsky Performance Status (KPS) ≥70%

• No prior systemic therapy (including neoadjuvant, adjuvant or vaccine therapy) for RCC

• Prior palliative radiotherapy ≥ 2 weeks before randomization

LVEF >45% (≤60 days before randomization)

Key Exclusion Criteria

• Active autoimmune disease or requirement for systemic immune suppressive agents

 Additional malignancy that is progressing or requires active treatment (certain) exceptions apply)

Major surgery or radiotherapy ≤14 days of randomization

• Tumor invading the superior vena cava, other major blood vessels, or the GI tract


• Any evidence of endotracheal or endobronchial tumor ≤30 days of randomization

Active infection requiring systemic therapy ≤14 days of randomization

STATUS

Study is open for enrollment

 For participating trial sites please visit https://clinicaltrials.gov, and search NCT03729245




REFERENCES

- Fyfe G, et al. *J Clin Oncol.* 1995;13:688–696.
- 2. McDermott DF, et al. J Clin Oncol. 2005;23:133-41.
- Klapper JA, et al. Cancer. 2008 Jul 15;113(2):293-301.
- Charych DH, et al. Clin Cancer Res. 2016;22:680-90.
- Bentebibel S, et al. [Published online ahead of print April 15 2019]. Cancer Discov. 2019. DOI: 10.1158/2159-8290.CD-18-1495.



Horizontal dotted lines indicate the thresholds for PD, PR and CR response according to RECIST (version 1.1) criteria; -100% is PR for complete clearance of target lesions. CR is a complete response, "u": Unconfirmed. *Best overall response is PD (SD for target lesions, PD for non-target lesions). §Off study treatment with confirmed PR due to patient decision.

Data cut date – 29 May 2018 and median time on study (5.6 months; n=26). As of data cut date, 48 patients were enrolled and received at least one dose of bempeg + NIVO. Per the protocol, the initial assessment of efficacy was based on the first 26 patients who were efficacy evaluable defined as \geq 1 post-baseline scan.



6. NCCN Guidelines Kidney Cancer v.42019 (25Aug2019). Motzer RJ, et al. N Engl J Med. 2007;356:115-24. Choueiri TK, et al. J Clin Oncol. 2017;35:591–597. 9. Motzer RJ, et al. N Engl J Med. 2018b;378(14):1277–90. 10. Rini BI, et al. N Engl J Med. 2019;380:1116–27. 11. Motzer RJ, et al. N Engl J Med. 2019;380:1103-1115. 12. Diab A, et al. Oral presentation at American Society of Clinical Oncology (ASCO) Annual Meeting; June 1–5, 2018; Chicago, IL, USA. Abstract 3006. 13. Mehta CR and Pocock SJ. Stat Med. 2011;30:3267-84.